Alkermes (ALKS) Non-Current Deffered Revenue (2011 - 2022)
Alkermes' (ALKS) quarterly Non-Current Deffered Revenue came in at $6.4 million in Q3 2022, down 50.25% year-on-year from $12.9 million in Q3 2021, and down 44.3% on a QoQ basis from $11.5 million in Q4 2021.
Alkermes (ALKS) Non-Current Deffered Revenue (2011 - 2022) Analysis & Trends
Alkermes (ALKS) has 12 years of Non-Current Deffered Revenue data on file, last reported at $6.4 million in Q3 2022.
- On a quarterly basis, Non-Current Deffered Revenue fell 50.25% year-over-year to $6.4 million in Q3 2022; TTM through Sep 2022 was $6.4 million, a 50.25% decrease from a year earlier, with the FY2021 full-year figure at $11.5 million, down 29.92% from the prior year.
- Non-Current Deffered Revenue for Q3 2022 stood at $6.4 million, down from $11.5 million in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for ALKS reached as high as $22.1 million in Q4 2019 and fell as low as $5.0 million in Q3 2018.
- Historically, Non-Current Deffered Revenue has averaged $12.8 million across 5 years, with a median of $11.6 million in 2019.
- Across the five-year window, Non-Current Deffered Revenue surged 131.69% in 2019 and sank 50.25% in 2022, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $9.5 million in 2018, then jumped by 131.69% to $22.1 million in 2019, then declined by 25.7% to $16.4 million in 2020, then fell by 29.92% to $11.5 million in 2021, then tumbled by 44.3% to $6.4 million in 2022.
- Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $6.4 million in Q3 2022, $11.5 million in Q4 2021, and $12.9 million in Q3 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 6.40 Mn |
| Dec 31, 2021 | 11.49 Mn |
| Sep 30, 2021 | 12.86 Mn |
| Jun 30, 2021 | 14.17 Mn |
| Mar 31, 2021 | 14.75 Mn |
| Dec 31, 2020 | 16.40 Mn |
| Sep 30, 2020 | 18.64 Mn |
| Jun 30, 2020 | 18.88 Mn |
| Mar 31, 2020 | 21.16 Mn |
| Dec 31, 2019 | 22.07 Mn |
| Sep 30, 2019 | 11.19 Mn |
| Jun 30, 2019 | 11.62 Mn |
| Mar 31, 2019 | 11.34 Mn |
| Dec 31, 2018 | 9.53 Mn |
| Sep 30, 2018 | 5.01 Mn |
| Jun 30, 2018 | 5.86 Mn |
| Mar 31, 2018 | 6.17 Mn |
| Dec 31, 2017 | 5.66 Mn |
| Sep 30, 2017 | 6.13 Mn |
| Jun 30, 2017 | 6.78 Mn |